Protein Sciences’ Flublok won the Food and Drug Administration’s approval in January thus introducing the world to the first recombinant trivalent hemagglutinin (rHA) influenza vaccine, based on a baculovirus expression system. This expression technology is fast becoming the killer app when it comes to producing vaccines efficiently and cost effectively. Genetic Engineering @ Biotechnology News correspondent Lina Genovesi highlights its successes in her report on the baculovirus expression technology track at the ISBiotech conference recently held in Arlington, Va.

Read the full story here